Balanced news tone
News Sentiment
IMVT sentiment intelligence
Immunovant Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
61 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+2.4% over one week, +18.1% over four weeks, trend active, and materially above fair value.
Form 4 Immunovant Inc For: 10 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
2.4%
Price confirming higher
Trend fit
Trend active
18.1% over four weeks
Fair value
50.6%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
16
Neutral
37
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
[144] Immunovant, Inc. SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immunovant (IMVT) director sells 1,500 shares after option exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
simplywall.st
Direct company coverage
Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 Jun 2026 07:00
- Source
- simplywall.st
Zacks
Direct company coverage
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 15:30
- Source
- Zacks
simplywall.st
Direct company coverage
Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Market source
Simply Wall St.
Direct company coverage
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 05 Jun 2026 08:12
- Source
- Simply Wall St.
Market source
Direct company coverage
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 02 Jun 2026 07:00
- Source
- Market source
Moomoo
Direct company coverage
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Moomoo
Market source
Direct company coverage
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 28 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
JPMorgan Raises Immunovant Price Target to $47 From $35, Overweight Rating Kept
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 26 May 2026 18:32
- Source
- MT Newswires
Market source
Direct company coverage
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
BofA raises Immunovant stock price target on higher peak sales outlook
- Tone
- Positive 82/100
- Event
- Guidance
- Published
- 21 May 2026 07:00
- Source
- Investing.com
Barron's
Direct company coverage
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Barron's
Quiver Quantitative
Direct company coverage
IMMUNOVANT ($IMVT) Releases Q4 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 20 May 2026 07:00
- Source
- Quiver Quantitative
Market source
Direct company coverage
Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 20 May 2026 07:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Quiver Quantitative
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Seeking Alpha
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Mar 2026 07:00
- Source
- Market source
The Motley Fool
Direct company coverage
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 11 Mar 2026 07:00
- Source
- The Motley Fool